Researchers at the University of Oulu have created a new method to analyze how individual patient tumor samples respond to drugs.This new pipeline is a major step towardpersonalized medicine because it addresses the difficulty in identifying the right drug, or combination of drugs, for each patient.
This pipeline uses live-cell barcoding to screen 96 drug treatments at single-cell resolution simultaneously.In a study focusing on high-grade serous ovarian cancer (HGSOC), the pipeline revealed the complex transcriptional landscape of tumors treated with 45 different drugs, representing 13 classes of mechanism of action.
Traditional cell line models often oversimplify the biology of real tumors, making it challenging to predict how a patient will respond to therapy.Working with primary patient samples not only improves the accuracy of these predictions but also opens the door to building a large-scale, data-driven “omics” database of drug responses.Researchers are hopeful that a comprehensive drug response database will significantly enhance the ability to match patients with the therapies most likely to be effective, ultimately improving outcomes in personalized cancer treatment.
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein September 2, 2025
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025